Galderma announced today the U.S. Food and Drug Administration (FDA) has approved Restylane Contour for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Restylane Contour, a new hyaluronic acid (HA) dermal filler, is Galderma’s first and only product in the U.S. formulated with XpresHAn Technology for the cheeks. XpresHAn Technology uses a unique manufacturing process which creates a smooth, injectable gel that integrates into the skin for natural, dynamic expression in motion.
Cheek filler searches have risen in popularity 218% from 2018-2020. Restylane Contour provides a treatment with high patient satisfaction.
“Cheeks are the cornerstone of the face, and focusing on natural contour and not just volume loss can result in a dynamic expression that amplifies their natural beauty.” said Dr. Leslie Baumann, M.D., a board-certified dermatologist in Miami and a lead investigator in the clinical trial of Restylane Contour. “Hyaluronic acid levels in the skin diminish as we age, causing the face to lose shape, while increasing the likelihood that wrinkles and folds will appear.”
“In the past, it was all about volume for the cheeks, but consumers today are looking for natural-looking results, such as the dynamic expression provided by XpresHAn Technology,” said Diane Gomez-Thinnes, Head of Galderma U.S. “Developed by leading innovators in the hyaluronic acid filler market, Restylane Contour delivers a treatment you can trust. While individual results may vary, 98% of Restylane Contour patients were pleased with their result at 1 year. The dynamic results truly speak for themselves.”
Read more at PR Newswire >>